Moberg Pharma announces prospectus regarding admission to trading of new shares

        Print
| Source: Moberg Derma AB
Not for announcement, publication or distribution, directly or indirectly, in or
into the U.S., Canada, Japan, Hong Kong, New Zealand, South Africa or
Australia.
The prospectus regarding the admission to trading of newly issued shares in
Moberg Pharma AB (publ) is now available on the company’s website
www.mobergpharma.se and in the company’s offices, at Gustavslundsvägen 42, 167
51 Bromma. Documents incorporated by reference in the prospectus are also
available in accordance with the above.

The prospectus has been prepared due to the admission to trading of the
2,068,965 new shares in Moberg Pharma, that were issued in connection with the
directed share issue to a limited group of Swedish and international
institutional qualified investors, which was resolved upon on May 27, 2014. The
newly issued shares are expected to be admitted to trading on NASDAQ OMX
Stockholm on or about June 18, 2014.

For further information, please contact:
Peter Wolpert, CEO
Mobile: +46 (0)70 - 735 71 35
Email: peter.wolpert@mobergpharma.se

Peter Östling, IR
Mobile: +46 (0)76 – 314 09 78
Email: peter.ostling@mobergpharma.se

About this information
The information provided herein is such that Moberg Pharma is required to
disclose pursuant to the Swedish Securities Markets Act and/or the Swedish
Financial Instruments Trading Act. The information was submitted for publication
at 08.30 am (CET) on June 18, 2014

Important information
Publication or distribution of this press release in certain jurisdictions may
be subject to restrictions according to law and the people in jurisdictions
where this press release has been made public or distributed should inform
themselves and follow such local restrictions. This press release does not
contain and does not constitute or form part of an invitation to acquire or
subscribe or a solicitation of any offer to buy or subscribe for shares,
subscription rights or other securities in Moberg Pharma.

This press release may not be published or distributed, directly or indirectly,
in or into the U.S., Canada, Japan, Hong Kong, New Zealand, South Africa,
Australia or in any other jurisdiction where such distribution would be
prohibited by applicable law. The information in this press release may not be
redistributed, reproduced or passed on in ways that conflict with applicable
restrictions. Failure to comply with these restrictions may constitute a
violation of the United States Securities Act of 1933 (“Securities Act”) or
applicable laws of other jurisdictions
About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with
a direct sales and marketing organization in the U.S. and an extensive
distributor network in more than 40 countries. The company’s OTC portfolio
includes the brands Kerasal®, Jointflex®, Kerasal Nail™, Domeboro®, Vanquish®,
and Fergon®. Kerasal Nail™ (Nalox™ in certain ex-U.S. markets) is the leading
product for the treatment of nail disorders in the U.S. and Nordic market. The
current portfolio will be supplemented by the acquisition and in-licensing of
additional products as well as product development with a focus on innovative
drug delivery of proven compounds. Moberg Pharma has offices in Stockholm and
New Jersey and the company’s shares (OMX: MOB) are listed on the Small Cap list
of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please
visit: www.mobergpharma.com.